Suppr超能文献

非酒精性脂肪性肝病:从发病机制到治疗的挑战

Nonalcoholic Fatty Liver Disease: A Challenge from Mechanisms to Therapy.

作者信息

Tarantino Giovanni, Citro Vincenzo, Capone Domenico

机构信息

Department of Clinical Medicine and Surgery, "Federico II" University Medical School of Naples, 80131 Naples, Italy.

Department of General Medicine, "Umberto I" Hospital, 84014 Nocera Inferiore (Sa), Italy.

出版信息

J Clin Med. 2019 Dec 19;9(1):15. doi: 10.3390/jcm9010015.

Abstract

Focusing on previously published mechanisms of non-alcoholic fatty liver disease (NAFLD), their uncertainty does not always permit a clear elucidation of the grassroot alterations that are at the basis of the wide-spread illness, and thus curing it is still a challenge. There is somehow exceptional progress, but many controversies persist in NAFLD research and clinical investigation. It is likely that hidden mechanisms will be brought to light in the near future. Hereby, the authors present, with some criticism, classical mechanisms that stand at the basis of NAFLD, and consider contextually different emerging processes. Without ascertaining these complex interactions, investigators have a long way left ahead before finding an effective therapy for NAFLD beyond diet and exercise.

摘要

聚焦于先前发表的非酒精性脂肪性肝病(NAFLD)机制,其不确定性并不总能清晰阐释这种广泛疾病所基于的根本改变,因此治愈它仍是一项挑战。NAFLD研究和临床调查虽有一些显著进展,但仍存在诸多争议。隐藏机制很可能在不久的将来被揭示出来。在此,作者带着一些批判性观点,介绍了构成NAFLD基础的经典机制,并考虑了不同背景下新出现的过程。在确定这些复杂相互作用之前,研究人员要找到除饮食和运动之外的NAFLD有效治疗方法还有很长的路要走。

相似文献

1
Nonalcoholic Fatty Liver Disease: A Challenge from Mechanisms to Therapy.
J Clin Med. 2019 Dec 19;9(1):15. doi: 10.3390/jcm9010015.
2
[Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
Yakugaku Zasshi. 2019;139(9):1147-1153. doi: 10.1248/yakushi.19-00011-1.
3
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
World J Gastroenterol. 2015 Apr 7;21(13):3777-85. doi: 10.3748/wjg.v21.i13.3777.
4
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology.
Yeungnam Univ J Med. 2019 May;36(2):67-77. doi: 10.12701/yujm.2019.00171. Epub 2019 Apr 11.
5
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539.
6
Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
Int J Mol Sci. 2016 Aug 23;17(9):1379. doi: 10.3390/ijms17091379.
7
Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
Transplantation. 2019 Jan;103(1):e1-e13. doi: 10.1097/TP.0000000000002480.
9
Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Am J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G462-G472. doi: 10.1152/ajpgi.00358.2018. Epub 2019 Jan 17.

引用本文的文献

2
The Role of TLRs in Obesity and Its Related Metabolic Disorders.
Int J Mol Sci. 2025 Mar 1;26(5):2229. doi: 10.3390/ijms26052229.
5
Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases-A comprehensive narrative review.
Food Sci Nutr. 2024 Feb 16;12(5):3097-3111. doi: 10.1002/fsn3.4010. eCollection 2024 May.
6
Cold-Pressed Sacha Inchi Oil: High in Omega-3 and Prevents Fat Accumulation in the Liver.
Pharmaceuticals (Basel). 2024 Feb 7;17(2):220. doi: 10.3390/ph17020220.
10
Understanding the Changing Landscape of Health Disparities in Chronic Liver Diseases and Liver Cancer.
Gastro Hep Adv. 2023;2(4):505-520. doi: 10.1016/j.gastha.2022.12.001. Epub 2022 Dec 15.

本文引用的文献

1
The Human Gut Virome Is Highly Diverse, Stable, and Individual Specific.
Cell Host Microbe. 2019 Oct 9;26(4):527-541.e5. doi: 10.1016/j.chom.2019.09.009.
2
Bilirubin reduces visceral obesity and insulin resistance by suppression of inflammatory cytokines.
PLoS One. 2019 Oct 2;14(10):e0223302. doi: 10.1371/journal.pone.0223302. eCollection 2019.
5
Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae.
Cell Metab. 2019 Oct 1;30(4):675-688.e7. doi: 10.1016/j.cmet.2019.08.018. Epub 2019 Sep 19.
6
The hepatokine Tsukushi gates energy expenditure via brown fat sympathetic innervation.
Nat Metab. 2019 Feb;1(2):251-260. doi: 10.1038/s42255-018-0020-9. Epub 2019 Jan 14.
7
Recombinant irisin induces weight loss in high fat DIO mice through increase in energy consumption and thermogenesis.
Biochem Biophys Res Commun. 2019 Nov 5;519(2):422-429. doi: 10.1016/j.bbrc.2019.08.112. Epub 2019 Sep 13.
8
Effect of Rifaximin Treatment on Endotoxemia and Insulin Sensitivity in Humans.
J Endocr Soc. 2019 Jun 26;3(9):1641-1651. doi: 10.1210/js.2019-00148. eCollection 2019 Sep 1.
9
Chronic exposure to Pb perturbs ChREBP transactivation and coerces hepatic dyslipidemia.
FEBS Lett. 2019 Nov;593(21):3084-3097. doi: 10.1002/1873-3468.13538. Epub 2019 Jul 27.
10
Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients.
Clin Gastroenterol Hepatol. 2020 Apr;18(4):855-863.e2. doi: 10.1016/j.cgh.2019.07.006. Epub 2019 Jul 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验